Publications by authors named "Quentin Berkovitch"
Article Synopsis
- - The study evaluates the cost-effectiveness of a cell-based quadrivalent influenza vaccine (QIVc) for people under 65 in France, which could avoid problems related to egg-based vaccines and potentially improve health outcomes.
- - Using a SEIR model based on data from 2011 to 2019, the research found that QIVc could prevent nearly 50,000 GP consultations, over 1,000 hospitalizations, and around 230 deaths compared to the traditional egg-based vaccine (QIVe).
- - Despite an initial cost of 7.6 million euros, QIVc ultimately saves the healthcare system 12 million euros, indicating it is a more effective and cost-saving strategy for influenza vaccination.
Background: In France, influenza accounts for an average of over one million consultations with GPs, 20,000 hospitalizations, and 9000 deaths per year, particularly among the over-65s. This study evaluates the cost-effectiveness of the adjuvanted quadrivalent influenza vaccine (aQIV) compared to standard (SD-QIV) and high-dose (HD-QIV) quadrivalent influenza vaccines for individuals aged 65 and older in France.
Methods: The age-structured SEIR transmission model, calibrated to simulate a mean influenza season, incorporates a contact matrix to estimate intergroup contact rates.